Use of Multiphoton Microscopy in the Diagnosis of Cancer - Full Text View

Sponsored by:	Weill Medical College of Cornell University
Information provided by:	Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:	NCT00652210

Purpose

Multiphoton microscopy (MPM) has been shown to be able to image tissue at a cellular level. Our project will initially evaluated the ability of MPM imaging to distinguish normal bladder urothelium from atypical and malignant urothelium in the ex vivo setting. After development of sufficient criteria, we plan to develop an endoscopic bladder probe that will provide a non-invasive means to image the interior of the bladder at the cellular level, which would provide direct evidence of the presence of tumor without a biopsy. After exhibiting usefulness of MPM imaging for bladder cancer, we will look at other organs beginning with the colon.

Condition	Intervention	Phase
Bladder Cancer Prostate Cancer	Other: Multiphoton microscopy	Phase I

Genetics Home Reference related topics: bladder cancer

MedlinePlus related topics: Bladder Cancer Cancer Prostate Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:	Use of Multiphoton Microscopy in the Diagnosis of Cancer

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:

After several delays, the multiphoton microscope has been delivered to Weill Cornell Medical College. We have been using this time to set-up and fine tune the multiphoton microscope. As of current, no negative events have occurred. [ Time Frame: 10/14/2007 to 2/15/2008 ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	October 2007
Estimated Study Completion Date:	March 2009
Estimated Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Intervention Details:

Use of multiphoton microscopy to diagnose cancer

Detailed Description:

Same as above

Eligibility

Ages Eligible for Study:	21 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Anyone who presents with bladder and/or prostate cancer

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00652210

Contacts

Contact: Ming-Ming Lee, B.A.

(212) 746-5467

mil2022@med.cornell.edu

Locations

United States, New York
Weill Cornell Medical College	Recruiting
New York, New York, United States, 10065
Principal Investigator: Douglas S. Scherr, M.D.

Sponsors and Collaborators

Weill Medical College of Cornell University

Investigators

Principal Investigator:

Douglas S Scherr, M.D.

Weill Cornell Medical College

More Information

Responsible Party:	Weill Cornell Medical College ( Douglas S. Scherr/Clinical Director of Urologic Oncology )
Study ID Numbers:	0506007919
Study First Received:	March 31, 2008
Last Updated:	July 21, 2008
ClinicalTrials.gov Identifier:	NCT00652210
Health Authority:	United States: Institutional Review Board

Keywords provided by Weill Medical College of Cornell University:

Bladder cancer
prostate cancer
multiphoton microscopy

Study placed in the following topic categories:

Cystocele
Prostatic Diseases
Genital Neoplasms, Male
Urologic Diseases
Urinary Bladder Diseases
Urinary Bladder Neoplasms

Urogenital Neoplasms
Genital Diseases, Male
Urologic Neoplasms
Prostatic Neoplasms
Urinary tract neoplasm
Bladder neoplasm

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009